Identification | Back Directory | [Name]
methyl 2-[3-({[3-(6-amino-2-butoxy-8-oxo-8,9-dihydro-7H-purin-9-yl)propyl][3-(morpholin-4-yl)propyl]amino}methyl)phenyl]acetate | [CAS]
866269-28-5 | [Synonyms]
AZD8848 AZD8848,AZD-8848 methyl 2-[3-({[3-(6-amino-2-butoxy-8-oxo-8,9-dihydro-7H-purin-9-yl)propyl][3-(morpholin-4-yl)propyl]amino}methyl)phenyl]acetate | [EINECS(EC#)]
642-434-9 | [Molecular Formula]
C29H43N7O5 | [MDL Number]
MFCD18633259 | [MOL File]
866269-28-5.mol | [Molecular Weight]
569.696 |
Hazard Information | Back Directory | [Uses]
AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitis[1]. | [in vivo]
AZD8848 (0.1-1 mg/kg; intratracheal) has a good pharmacokinetics in the Brown Norway rat[1]. ?
AZD8848 (0.3 mg/kg; Intratracheal) suppresses the ovalbumin (OVA) challenge in the rat allergy model[1].
Animal Model: | Brown Norway rat allergy model[1] | Dosage: | 0.1 mg/kg, 1 mg/kg | Administration: | Intratracheal (24 hours prior to and 24 hours after the OVA challenge) | Result: | Suppressed OVA challenge in a dose-dependent manner. |
Animal Model: | Brown Norway rat[1] | Dosage: | 0.3 mg/kg (Pharmacokinetic Analysis) | Administration: | Intratracheal | Result: | Has a very short half-life (0.2 min) in rat blood and declined slowly after this point and levels above 1000 nmol/kg were maintained for over 5 hours. |
| [IC 50]
TLR7 | [References]
[1] Delaney S, et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848. BMJ Open Respir Res. 2016 Feb 23;3(1):e000113. DOI:10.1136/bmjresp-2015-000113 |
|
|